CA-NEXTIVITY
15.3.2022 07:02:04 CET | Business Wire | Press release
Nextivity today announced that Nordic distributor Tura Scandinavia AB has the first European installation of Cel-Fi QUATRA 4000e underway. The new multi-carrier hybrid active DAS (distributed antenna system) for the EMEA market has been deployed at Elgiganten and Rusta stores in northern Stockholm, Sweden so customers and employees can now use their cell phones anywhere inside the stores, and experience good quality reception.
Spotty cellular coverage, poor voice quality, dropped calls, and dead zones continue to impact employees and customers in many retail buildings. Cel-Fi QUATRA 4000e is an affordable, all-digital, multi-carrier active DAS hybrid solution that solves this issue by providing uniform, high quality cellular signal throughout any commercial building. This industry-leading system is also carrier approved and guaranteed network safe.
“There was no cellular reception at all inside the Elgiganten and Rusta stores due to the metal construction of the buildings, which is common for commercial property in Sweden,” says Terje Skatterod, Senior Technology Officer at Tura Scandinavia, a Nordic distributor that offers mobile, data, and cellular equipment for retailers through a network of system integrators. “Cel-Fi QUATRA has improved the signal inside the stores by 25 dBM, which is equivalent to increasing the coverage by almost 100 times.”
“As Cel-Fi QUATRA is 5G-ready, building owners get a greater return on their investment with this modern solution which is upgradable,” explains Sverre Platou, Nextivity Brand Manager at Tura Scandinavia. “The system is also all-digital, using ethernet rather than coax cabling, which makes installation easier and reduces the installation cost to about a quarter of traditional repeater systems.”
“Cel-Fi QUATRA is starting to get a lot of attention in the Nordic region. Unlike other equipment, you don't need the RF skills to install it. You can simply use a local electrician to run the cabling and hook it up to the internet, and one telecom RF engineer to deploy the whole solution remotely,” Skatterod says.
Tura Scandinavia, which was named best European distributor in 2021 by Nextivity, has several installations of the new Cel-Fi QUATRA 4000e scheduled for other retailers in Sweden and throughout Europe. For more information about QUATRA, visit cel-fi.com/buy .
“Tura Scandinavia is a strong strategic partner for Nextivity, bringing our best-in-class cellular coverage solutions to the reseller community,” says David Cabanes, Nextivity Vice-President of European Sales. “With product offerings now available for enterprise, small and mid-size businesses, mobile, and micro solutions, we look forward to continuing to work with Tura Scandinavia to help their partners expand their capabilities and market reach.”
About Tura Scandinavia AB
Tura Scandinavia AB is a leading Nordic distributor of accessories in Audio, Video, Mobile, Data, Photography, TV, Gaming and SDA. Our philosophy is: a wide range, strong brands and fast delivery. The business was founded in Gothenburg in 1976 and we currently operate in Sweden, Denmark, Finland and Norway. The head office is located in Kungsbacka and the logistics center in Nässjö, Sweden.
About Nextivity
Headquartered in San Diego, Nextivity Inc. develops the award-winning, Cel-Fi family of products that deliver best-in-class connectivity for enterprise, business, residential spaces, and mobile cellular and public safety communication needs. Cel-Fi is the go-to solution for healthcare, government, hotels, retail, education, remote sites, parking garages, manufacturing, warehouses, as well as trucking and marine fleets. Cel-Fi products are available in 100 countries through mobile operators and a growing worldwide network of master distributors, systems integrators, installers, and resellers. Additional information is available at cel-fi.com , on Twitter , LinkedIn , and on Facebook .
Nextivity, the Nextivity logo, Cel-Fi, Smart Signal Booster, and Supercell are registered trademarks of Nextivity Incorporated in the United States and/or other countries. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005864/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom